PT  - JOURNAL ARTICLE
AU  - Colman, Ewan
AU  - Enright, Jessica
AU  - Puspitarani, Gavrila A.
AU  - Kao, Rowland R.
TI  - Estimating the proportion of SARS-CoV-2 infections reported through diagnostic testing
AID  - 10.1101/2021.02.09.21251411
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.09.21251411
4099  - http://medrxiv.org/content/early/2021/02/10/2021.02.09.21251411.short
4100  - http://medrxiv.org/content/early/2021/02/10/2021.02.09.21251411.full
AB  - The number of positive diagnostic tests for SARS-CoV-2 is a critical metric that is commonly used to assess epidemic severity and the efficacy of current levels of control. However, a proportion of individuals infected with SARS-CoV-2 may never receive a diagnostic test, while many of those who are tested may receive a false negative result. Consequently, cases reported through testing of symptomatic individuals represent only a fraction of the total number of infections, and this proportion is expected to vary depending on changes in natural factors and variability in test-seeking behaviour. Here we combine a number of data sources from England to estimate the proportion of infections that have resulted in a positive diagnosis. Using published estimates of the incubation period distribution and time-dependent test sensitivity, we estimate SARS-CoV-2 incidence from daily reported diagnostic test data. By calibrating this estimate against surveillance data we find that approximately 25% of infections were consistently reported through diagnostic testing before November 2020. This percentage increased through the final months of 2020, predominantly in regions with a large presence of the the UK variant of concern (VOC), before falling rapidly in the last two weeks of January 2021. These changes are not explained by variation in rates of lateral flow device or PCR testing, but are consistent with there being an increased probability for the VOC that infection will result in an eventual positive diagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received to support this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was not required forthis workAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are taken from publicly available sources referenced within the manuscript